HEMOFIL M

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
HEMOFIL M
Generic name
ANTIHEMOPHILIC FACTOR HUMAN
Manufacturer
Takeda Pharmaceuticals America, Inc.
Product type
PLASMA DERIVATIVE
SPL set ID
b8953ff7-3bba-4a0b-a486-f26fb81f05d9
SPL ID
15c108eb-91a2-4058-9d08-cc1168ee741d
Version
15
Effective date
2025-03-06
Source export date
2026-11-13
Source partition
10
Source file
https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:15:32

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 4 matching rows.

warnings

WARNINGS Hypersensitivity Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with HEMOFIL M and have been manifested by bronchospasm, dyspnea, hypotension, chest pain, facial edema, urticaria, rash, flushing, pruritus, and nausea. Neutralizing Antibodies The development of neutralizing antibodies (inhibitors) to Factor VIII is a known complication of the treatment of patients with Hemophilia A. Inhibitors have predominantly been reported in previously untreated patients. The risk of developing inhibitors is correlated to the extent of exposure to Factor VIII, the risk being highest within the first 20 exposure days, and to other genetic and environmental factors. The risk for inhibitor development depends on a number of factors relating to the characteristics of the patient (e.g., type of the Factor VIII gene mutation, family history, ethnicity), which are believed to represent the most significant risk factors for inhibitor formation. Transmission of Infectious Agents Because HEMOFIL M is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . The physician should discuss the risks and benefits of this product with the patient. Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly non-A, non-B hepatitis. As indicated under Clinical Pharmacology , however, a group of such patients treated with HEMOFIL M did not demonstrate signs or symptoms of non-A, non-B hepatitis over observation periods ranging from three to nine months.

warnings

Hypersensitivity Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with HEMOFIL M and have been manifested by bronchospasm, dyspnea, hypotension, chest pain, facial edema, urticaria, rash, flushing, pruritus, and nausea.

warnings

Neutralizing Antibodies The development of neutralizing antibodies (inhibitors) to Factor VIII is a known complication of the treatment of patients with Hemophilia A. Inhibitors have predominantly been reported in previously untreated patients. The risk of developing inhibitors is correlated to the extent of exposure to Factor VIII, the risk being highest within the first 20 exposure days, and to other genetic and environmental factors. The risk for inhibitor development depends on a number of factors relating to the characteristics of the patient (e.g., type of the Factor VIII gene mutation, family history, ethnicity), which are believed to represent the most significant risk factors for inhibitor formation.

warnings

Transmission of Infectious Agents Because HEMOFIL M is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . The physician should discuss the risks and benefits of this product with the patient. Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some viral infections, particularly non-A, non-B hepatitis. As indicated under Clinical Pharmacology , however, a group of such patients treated with HEMOFIL M did not demonstrate signs or symptoms of non-A, non-B hepatitis over observation periods ranging from three to nine months.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 2 · 5 matching rows.

adverse reactions

ADVERSE REACTIONS Adverse Reactions from Clinical Trials The adverse reactions presented in this section have been identified based on clinical trial experience with HEMOFIL M in patients previously treated with other Factor VIII concentrates or blood products (N = 74), and previously untreated patients (PUPs; N = 50). Clinical Trial Adverse Reactions System Organ Class (SOC) Preferred MedDRA Term Number of Cases (Frequency Percentage) BLOOD AND LYMPHATIC SYSTEM DISORDERS Factor VIII inhibition 3 (5.7%) In a study that included 43 evaluable PUPs and 10 minimally treated patients (MTPs), i.e., patients with a single exposure to other Factor VIII concentrates or blood products, 3 of the total of 53 patients (5.7%) developed an inhibitor while on study. NERVOUS SYSTEM DISORDERS Dizziness 1 (0.8%) Headache 1 (0.8%) Dysgeusia 1 (0.8%) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Pyrexia 1 (0.8%) Infusion site inflammation 2 (1.6%) HEMOFIL M was administered to 11 patients previously untreated with Antihemophilic Factor (Human). They have shown no signs of hepatitis or HIV infection following three to nine months of evaluation. A study of 25 patients treated with HEMOFIL M and monitored for three to six months has demonstrated no evidence of antibody response to mouse protein. More than 1,000 infusions of HEMOFIL M have been administered during the clinical trials. Reported events included a single episode each of chest tightness, fuzziness and dizziness, and one patient reported an unusual taste after each infusion. Post-marketing Adverse Reactions In addition to clinical trials, the following adverse reactions have been reported in the post-marketing experience, listed by MedDRA System Organ Class (SOC), then by Preferred Term. Immune System Disorders : anaphylactic reaction, hypersensitivity Eye Disorders : visual impairment, ocular hyperemia Cardiac Disorders : cyanosis, bradycardia, tachycardia Vascular Disorders : hypotension, flushing Respiratory, Thoracic, and Mediastinal Disorders : bronchospasm, dyspnea, cough, hyperventilation Gastrointestinal Disorders : diarrhea, vomiting, nausea, abdominal pain Skin and Subcutaneous Tissue Disorders : urticaria, rash, pruritus, hyperhidrosis Musculoskeletal and Connective Tissue Disorders : musculoskeletal pain General Disorders and Administration Site Conditions : facial edema, edema, chills, fatigue, chest pain, irritability

adverse reactions

Adverse Reactions from Clinical Trials The adverse reactions presented in this section have been identified based on clinical trial experience with HEMOFIL M in patients previously treated with other Factor VIII concentrates or blood products (N = 74), and previously untreated patients (PUPs; N = 50). Clinical Trial Adverse Reactions System Organ Class (SOC) Preferred MedDRA Term Number of Cases (Frequency Percentage) BLOOD AND LYMPHATIC SYSTEM DISORDERS Factor VIII inhibition 3 (5.7%) In a study that included 43 evaluable PUPs and 10 minimally treated patients (MTPs), i.e., patients with a single exposure to other Factor VIII concentrates or blood products, 3 of the total of 53 patients (5.7%) developed an inhibitor while on study. NERVOUS SYSTEM DISORDERS Dizziness 1 (0.8%) Headache 1 (0.8%) Dysgeusia 1 (0.8%) GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Pyrexia 1 (0.8%) Infusion site inflammation 2 (1.6%) HEMOFIL M was administered to 11 patients previously untreated with Antihemophilic Factor (Human). They have shown no signs of hepatitis or HIV infection following three to nine months of evaluation. A study of 25 patients treated with HEMOFIL M and monitored for three to six months has demonstrated no evidence of antibody response to mouse protein. More than 1,000 infusions of HEMOFIL M have been administered during the clinical trials. Reported events included a single episode each of chest tightness, fuzziness and dizziness, and one patient reported an unusual taste after each infusion.

adverse reactions

Post-marketing Adverse Reactions In addition to clinical trials, the following adverse reactions have been reported in the post-marketing experience, listed by MedDRA System Organ Class (SOC), then by Preferred Term. Immune System Disorders : anaphylactic reaction, hypersensitivity Eye Disorders : visual impairment, ocular hyperemia Cardiac Disorders : cyanosis, bradycardia, tachycardia Vascular Disorders : hypotension, flushing Respiratory, Thoracic, and Mediastinal Disorders : bronchospasm, dyspnea, cough, hyperventilation Gastrointestinal Disorders : diarrhea, vomiting, nausea, abdominal pain Skin and Subcutaneous Tissue Disorders : urticaria, rash, pruritus, hyperhidrosis Musculoskeletal and Connective Tissue Disorders : musculoskeletal pain General Disorders and Administration Site Conditions : facial edema, edema, chills, fatigue, chest pain, irritability

adverse reactions table

<table width="100%"><col width="35%"/><col width="33%"/><col width="32%"/><tbody><tr><td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Clinical Trial Adverse Reactions</content></paragraph></td></tr><tr><td align="center" styleCode="Lrule Botrule " valign="top"><paragraph><content styleCode="bold">System Organ Class (SOC)</content></paragraph></td><td align="center" styleCode="Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Preferred MedDRA Term</content></paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph><content styleCode="bold">Number of Cases</content></paragraph><paragraph><content styleCode="bold">(Frequency</content></paragraph><paragraph><content styleCode="bold">Percentage)</content></paragraph></td></tr><tr><td styleCode="Lrule Botrule " valign="top"><paragraph><content styleCode="bold">BLOOD AND LYMPHATIC</content></paragraph><paragraph><content styleCode="bold">SYSTEM DISORDERS</content></paragraph></td><td styleCode="Lrule Botrule " valign="middle"><paragraph>Factor VIII inhibition</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="middle"><paragraph>3 (5.7%)<footnote ID="_RefID0B1990E431FA4641B20FACAB3F077453">In a study that included 43 evaluable PUPs and 10 minimally treated patients (MTPs), i.e., patients with a single exposure to other Factor VIII concentrates or blood products, 3 of the total of 53 patients (5.7%) developed an inhibitor while on study.</footnote></paragraph></td></tr><tr><td rowspan="3" styleCode="Lrule Botrule " valign="top"><paragraph><content styleCode="bold">NERVOUS SYSTEM DISORDERS</content></paragraph></td><td styleCode="Lrule Botrule " valign="top"><paragraph>Dizziness</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1 (0.8%)</paragraph></td></tr><tr><td styleCode="Lrule Botrule " valign="top"><paragraph>Headache</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1 (0.8%)</paragraph></td></tr><tr><td styleCode="Lrule Botrule " valign="top"><paragraph>Dysgeusia</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1 (0.8%)</paragraph></td></tr><tr><td rowspan="2" styleCode="Lrule Botrule " valign="top"><paragraph><content styleCode="bold">GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</content></paragraph></td><td styleCode="Lrule Botrule " valign="top"><paragraph>Pyrexia</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>1 (0.8%)</paragraph></td></tr><tr><td styleCode="Botrule Lrule " valign="top"><paragraph>Infusion site inflammation</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>2 (1.6%)</paragraph></td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.